Citations

Clear

9383 citation(s) found for "Thomas, PS".

Buildup of image quality in view‐shared time‐resolved 3D CE‐MRA
Johnson, Casey P. , Polley, Thomas W., Glockner, James F., Young, Phillip M. , Riederer, Stephen J.

Mayo Clinic

Magnetic Resonance in Medicine | August 30, 2012 | Volume: 70 | Issue: 2 | Pages: 348-357

10.1002/mrm.24466 | PMID 22936574 Get It

Time‐resolved three‐dimensional contrast‐enhanced MR angiography often relies on view sharing of peripheral k‐space data to enable acquisition of angiograms with both high spatial resolution and a rapid frame rate. It is typically assumed that k‐space will be fully sampled during passage of the contrast bolus arterial phase. However, this is not the case when view sharing is incomplete, for example, at the leading edge of an enhancing vessel or if acquisition time is limited as in fluoroscopic tracking for multistation bolus chase MR angiography. Incomplete view sharing will degrade image quality, for example, by reducing vessel signal and sharpness and increasing undersampling artifacts. In this work, the evolution of angiogram quality with view sharing is quantitatively assessed in phantom experiments and in vivo contrast‐enhanced MR angiography calf studies. It is demonstrated that there are multiple sets of sequence parameters that can yield a target image update time, but the choice of parameters can profoundly affect how image quality evolves with view sharing. A fundamental tradeoff between vessel signal and sharpness and its relationship to the sequence temporal footprint is investigated and discussed. Magn Reson Med 70:348–357, 2013. © 2012 Wiley Periodicals, Inc.
Human Lupus Serum Induces Neutrophil-Mediated Organ Damage in Mice That Is Enabled by Mac-1 Deficiency
Rosetti, Florencia , Tsuboi, Naotake , Nishi, Hiroshi , Ernandez, Thomas , Sethi, Sanjeev , Croce, Kevin , Stavrakis, George, Alcocer‐Varela, Jorge, Gómez‐Martín, Diana , Rooijen, Nico van , Lichtman, Andrew H., Mayadas, Tanya N. , Chen, Kan , Kyttaris, Vasileios C. , Tsokos, George C.

Mayo Clinic

The Journal of Immunology | August 30, 2012 | Volume: 189 | Issue: 7 | Pages: 3714-3723

10.4049/jimmunol.1201594 | PMID 22933624 Get It

Abstract Systemic lupus erythematosus (SLE) is a chronic, multiorgan inflammatory autoimmune disorder associated with high levels of circulating autoantibodies and immune complexes. We report that passive transfer of human SLE sera into mice expressing the uniquely human FcγRIIA and FcγRIIIB on neutrophils induces lupus nephritis and in some cases arthritis only when the mice additionally lack the CD18 integrin, Mac-1. The prevailing view is that Mac-1 on macrophages is responsible for immune complex clearance. However, disease permitted by the absence of Mac-1 is not related to enhanced renal immune complex deposition or in situ C1q/C3 complement activation and proceeds even in the absence of macrophages. Instead, disease is associated with increased FcγRIIA-induced neutrophil accumulation that is enabled by Mac-1 deficiency. Intravital microscopy in the cremasteric vasculature reveals that Mac-1 mitigates FcγRIIA-dependent neutrophil recruitment in response to deposited immune complexes. Our results provide direct evidence that human SLE immune complexes are pathogenic, demonstrate that neutrophils are primary mediators of end organ damage in a novel humanized lupus mouse model, and identify Mac-1 regulation of FcγRIIA-mediated neutrophil recruitment as a key step in development of target organ damage.
Should neurointerventional fellowship training be suspended indefinitely?
Hirsch, Joshua A , Rasmussen, Peter A. , Hussain, Muhammad Shazam , Frei, Donald , Meyers, Phil M., Jabbour, Pascal , Gonzalez, L. Fernando , Turk, Aquilla S , Turner, Raymond D , Arthur, Adam S , Gupta, Rishi , Cloft, Harry J. , Fiorella, David , Woo, Henry Hyunshik , Hui, Ferdinand , Mocco, J , Arthur, Adam Stephen

Mayo Clinic

Journal of NeuroInterventional Surgery | August 29, 2012 | Volume: 4 | Issue: 5 | Pages: 315-318

10.1136/neurintsurg-2012-010471 | PMID 22933732 Get It

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group
Husain, Aliya N. , Colby, Thomas V. , Ordóǹez, Nelson G., Krausz, Thomas, Attanoos, Richard , Beasley, Mary Beth , Borczuk, Alain , Butnor, Kelly J. , Cagle, Philip T., Chirieac, Lucian R. , Đačić, Sanja , Fraire, Armando E., Galateau-Sallé, Françoise , Gibbs, A R, Gown, Allen M. , Hammar, Samuel P. , Litzky, Leslie A., Marchevsky, Alberto M. , Roggli, Victor L., Wick, Mark R. , Churg, Andrew , Nicholson, Andrew G. , Travis, William D.

Mayo Clinic

Archives of Pathology and Laboratory Medicine | August 28, 2012 | Volume: 137 | Issue: 5 | Pages: 647-667

10.5858/arpa.2012-0214-oa | PMID 22929121 Get It

Context .—Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. Objective .—To provide updated practical guidelines for the pathologic diagnosis of MM. Data Sources .—Pathologists involved in the International Mesothelioma Interest Group and others with an interest in the field contributed to this update. Reference material includes peer-reviewed publications and textbooks. Conclusions .—There was consensus opinion regarding (1) distinction of benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiation of epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas, and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory. Immunohistochemical panels should contain both positive and negative markers. It is recommended that immunohistochemical markers have either sensitivity or specificity greater than 80% for the lesions in question. Interpretation of positivity generally should take into account the localization of the stain (eg, nuclear versus cytoplasmic) and the percentage of cells staining (>10% is suggested for cytoplasmic membranous markers). These guidelines are meant to be a practical reference for the pathologist.
Faculty Opinions recommendation of Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.
Habermann, Thomas M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 21, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1166560.904063 Get It

Faculty Opinions recommendation of Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy.
Habermann, Thomas M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 21, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.2983957.2660056 Get It

Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study
Friedberg, Jonathan W. , Byrtek, Michelle, Link, Brian K. , Flowers, Christopher R. , Hainsworth, John D. , Cerhan, James R. , Zelenetz, Andrew D. , Hirata, Jamie , Miller, Thomas P. , Taylor, Michael D. , Cerhan, James R , Link, Brian K , Zelenetz, Andrew D

Mayo Clinic

Journal of Clinical Oncology | August 21, 2012 | Volume: 30 | Issue: 27 | Pages: 3368-3375

10.1200/jco.2011.40.6546 | PMID 22915662 Get It

PurposeThe optimal management of stage I follicular lymphoma, according to consensus guidelines, is based on uncontrolled experiences of select institutions. Diverse treatment approaches are used despite guidelines that recommend radiation therapy (XRT).Patients and MethodsWe analyzed outcomes of patients with stage I follicular lymphoma enrolled onto the National LymphoCare database.ResultsOf 471 patients with stage I follicular lymphoma, 206 patients underwent rigorous staging as defined by both a bone marrow aspirate and biopsy and an imaging study (a computed tomography [CT] scan of the whole body, a positron emission tomography [PET]/CT scan, or both). Rigorously staged patients had superior progression-free survival (PFS) compared with nonrigorously staged patients (hazard ratio [HR], 0.63). Treatments given to rigorously staged patients were rituximab/chemotherapy (R-chemo; 28%), XRT (27%), observation (17%), systemic therapy + XRT (13%), rituximab monotherapy (12%), and other (3%). With a median follow-up of 57 months for PFS, there were 44 progression events (in 21% of patients) for rigorously staged patients. For these patients, PFS was significantly improved with either R-chemo or systemic therapy + XRT compared with patients receiving XRT alone after adjustment for histology, LDH, and the presence of B symptoms. There were no differences in overall survival.ConclusionIn this largest, prospectively enrolled group of patients with stage I follicular lymphoma, variable treatment approaches resulted in similar excellent outcomes, which challenges the paradigm that XRT should be standard for this presentation.
Faculty Opinions recommendation of Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Habermann, Thomas M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 21, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.5674990.6384058 Get It

Faculty Opinions recommendation of Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Habermann, Thomas M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.6374956.6473054 Get It

Faculty Opinions recommendation of The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.
Habermann, Thomas M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.8536957.11931054 Get It